Expansion Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: San Diego CA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT03959189
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Expansion Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

flumazenil (mazicon ) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myotonic Dystrophy (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1